)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bio-Path
Bio-Path (BPTH) investor relations material
Bio-Path has been otc
Bio-Path Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary20 May, 2026
Executive summary
Focused on RNAi nanoparticle drug development for oncology and obesity, with four drug candidates in development targeting cancer and metabolic diseases.
Lead candidate prexigebersen is in a Phase 2 trial for AML, with promising interim results; other candidates target Bcl-2, STAT3, and obesity-related pathways.
Operations paused and most employees furloughed as of June 2025 due to capital constraints; seeking additional financing and strategic partnerships.
Financial highlights
Net loss for Q1 2026 was $0.3 million, a significant decrease from $2.9 million in Q1 2025, driven by reduced R&D and G&A expenses.
Cash balance at March 31, 2026 was $0.1 million, up slightly from year-end 2025, but insufficient for 12 months of operations.
Stockholders’ deficit increased to $(8.5) million as of March 31, 2026.
No revenue generated in Q1 2026.
Outlook and guidance
Expects to continue incurring significant operating losses and require substantial additional capital for ongoing and future clinical trials.
Future operations depend on successful fundraising, licensing, or partnership agreements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bio-Path
- Operational pause, depleted cash, and debt defaults highlight urgent need for new funding.BPTH
Q3 2025 - Registering 17.8M shares for resale from recent warrants, with proceeds for working capital if exercised.BPTHRegistration Filing
- Registering 5.57M shares for resale, with future warrant proceeds to fund operations.BPTHRegistration Filing
- Key votes include director elections, auditor ratification, stock plan amendment, and reverse split.BPTHProxy Filing
- Shareholders will vote on director elections, auditor ratification, stock plan, reverse split, and private placement.BPTHProxy Filing
- Key votes include director elections, auditor ratification, stock plan amendment, and reverse split.BPTHProxy Filing
- Pipeline expanded beyond oncology; Q3 loss narrowed, but cash and Nasdaq risks remain.BPTHQ3 2024
- Strong AML remission rates and pipeline progress showcased, supported by robust IP and cash.BPTHH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q2 net loss narrowed, cash rose, clinical pipeline advanced, but liquidity risks remain.BPTHQ2 2024
Bio-Path
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bio-Path Holdings Inc. is a biotechnology company focused on the development of RNAi-based therapies for cancer treatment. The company uses its proprietary DNAbilize® platform to design lipid-delivered RNAi therapeutics that target specific proteins involved in cancer cell survival and proliferation. Bio-Path’s lead programs focus on treating hematologic cancers such as leukemia and lymphoma. The company’s approach aims to provide innovative treatment options for patients with unmet medical needs in oncology. The company is headquartered in Bellaire, Texas, USA, and its shares are listed on the NASDAQ.